Abatacept

Nature Reviews Drug Discovery

Volumn 5, Issue 3, 2006, Pages 185-186

  Moreland, Larry ^a   Bate, Guy ^b   Kirkpatrick, Peter ^c  

^a University of Alabama at Birmingham   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CERTOLIZUMAB PEGOL; CIMZIA; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 2; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; DEMYELINATING DISEASE; DRUG APPROVAL; DRUG BINDING SITE; DRUG COST; DRUG MARKETING; DRUG RECEPTOR BINDING; ECONOMIC EVALUATION; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTE ACTIVATION; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 33644761940     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1989     Document Type: Note

References (12)

1. Smolen, J. S. & Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nature Rev. Drug Discov. 2, 473-488 (2003).
2. Reiser H. & Stadecker, M. J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N. Engl. J. Med. 335, 1369-1377 (1996).
3. Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569 (1991).
4. Linsley, P. S. et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257, 792-795 (1992).
5. FDA labelling information [online], (2005).
6. Webb, L. M., Walmsley, M. J. & Feldmann, M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2. Eur. J. Immunol. 26, 2320-2328 (1996).
7. Moreland, L. W. et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46, 1470-1479 (2002).
8. Kremer J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
9. Genovese, M. C. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353, 1114-1123 (2005).
10. Lipsky, P. E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343, 1594-1602 (2000).
11. Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomized controlled trial. Lancet 363, 675-681 (2004).
12. Breedveld, F. C. et al. The PREMIER Study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006).